Table 2.
Observed adverse events following IGEV-Bv salvage and Bv consolidation
| Adverse event | Entire cohort (n = 28) |
|---|---|
| Neutropenia grades 3–4, n (%) | 27 (96) |
| Thrombocytopenia grades 3–4, n (%) | 25 (89) |
| Blood transfusion units, median (range) | 2 (0–11) |
| Mucositis, n (%) | |
| Grades 1–2 | 5 (18) |
| Grade 3 | 1 (4) |
| Febrile neutropenia, n (%) | 16 (57) |
| Peripheral neuropathy on salvage, n (%) | |
| Grades 1–2 | 2 (7) |
| Grade 3 | 1 (4) |
| Diarrhea, n (%) | 6 (21) |
| Transaminitis grades 3–4, n (%) | 2 (7) |
| Acute renal injury, n (%) | 0 |
| ICU transfer, n (%) | 0 |
| Bv consolidation, n (%) | 18 (64) |
| Indication for Bv consolidation, n (%) | |
| Remission < 12 Months | 13 (72) |
| B-symptoms at Relapse | 3 (17) |
| Extranodal Relapse | 2 (11) |
| Total doses of Bv delivered, median (range) | 15 (6–16) |
| Filgrastim given during Bv consolidation, n (%) | 7 (39) |
| Peripheral neuropathy on consolidation, n (%) | |
| Grades 1–2 | 4 (22) |
| Grade 3 | 1 (5) |
| Bv dose reduced due to AE, n (%) | 6 (33) |
HCT hematopoietic stem cell transplant, ICU intensive care unit, IGEV-Bv ifosfamide, gemcitabine, and vinorelbine with brentuximab vedotin, AE adverse events